Benefits of cyclosporine microemulsion (Neoral) C2 monitoring are sustained at 1 year in de novo liver transplant recipients

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)3092-3093
Number of pages2
JournalTransplantation proceedings
Volume33
Issue number7-8
DOIs
StatePublished - 2001

Bibliographical note

Funding Information:
Supported by Novartis Pharma AG, Basel, Switzerland.

Cite this